Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
08 December 2020 | Story Leonie Bolleurs | Photo Supplied
At the BJCP beer judging competition, Dr Errol Cason won Best of Show with his Belgian Saison. Here he is presenting at the AfricaBrew2020 Brewing conference.
Staff and students from the University of the Free State (UFS) once again proved their skills in beer homebrewing when they walked away with one first place and two second places at the 13th annual Anheuser-Busch Inbev (AB-Inbev) – formally South African Breweries (SAB) – intervarsity beer brewing and tasting competition, and the Beer Judging Certification Programme (BJCP) competition held at the AfricaBrew2020 Brewing conference. Both these events took place over the weekend of 27 and 28 November 2020.

Evil Twin Double and Three Sips German 

Competing in the AB-Inbev/SAB Intervarsity brewing and tasting competition, was a group of students from the UFS Department of Microbial, Biochemical and Food Biotechnology, consisting of Eduvan Bischoff (PhD student), Elzette van der Walt (MSc student), Culien van der Merwe (MSc student), Gunther Staats (MSc student), and Twyne Skein (MSc student). This team came second in both the Indian Pale Ale (IPA) category with their Evil Twin Double IPA and in the Lager category with their Three Sips German Pils. 

“This is an outstanding accomplishment. Congratulations also go to our fellow Free Stater’s at the Central University of Technology (CUT) for winning the India Pale Ale (IPA) category as well as best overall beer with their New England IPA,” commented Dr Errol Cason, Senior Lecturer in the UFS Department of Animal Science, also representing the liquid yeast company LiquidCulture Yeast.

According to Dr Cason, this SAB-sponsored competition sees students from local universities brew and enter beers for judging, and competing for prizes, including the coveted ‘Best of Show’ trophy. 

“This event also aims to promote beer culture along with responsible drinking, by hosting talks by industry experts where students can interact with commercial brewers, scientists, and marketers,” says Dr Cason. 

The event was hosted by South African Breweries (SAB) and CUT, through the Centre for Applied Food Sustainability and Biotechnology (CAFSaB), in association with the UFS. 

Although the event was moved online in 2020 due to the international pandemic, it did not mean that there was a decline in the quality of presentations, or in the beer entered by universities. – D r Errol Cason

Dr Cason explains that entrants are usually challenged to brew beers according to the 2015 Beer Judge Certification Programme (BJCP) guidelines in lager, IPA, winter warmer, and fruit beer categories. 

“This year included the African Premium Ale and Lockdown Brew categories as well, where teams were mostly left to invent and experiment on their own with a few rules, such as using only indigenous African ingredients or ingredients that were available in supermarkets during lockdown,” says Dr Cason. 

There is also an award for the best bottle dress (label). 

Dr Cason believes that although the event was moved online in 2020 due to the international pandemic, it did not mean that there was a decline in the quality of presentations, or in the beer entered by universities. 

Belgian Saison and Extra Special Bitter

He and Christopher Rothmann, who is busy with a PhD in Biotechnology at the UFS and is co-founder of the company LiquidCulture (LC) Yeast, attended and presented at the AfricaBrew2020 Brewing conference. AfricaBrew is an annual brewing conference specialising in workshops and demonstrations for home and professional brewers. 

Accompanying the conference is a BJCP beer judging competition where all home and professional brewers can enter beers. During this competition, Dr Cason won Best of Show with his Belgian Saison. Rothmann came second with his Extra Special Bitter.

Since LiquidCulture Yeast was found in 2018, this commercial venture has since spun out and are now providing liquid brewing yeast to the homebrewing and commercial brewing industry. Rothmann and Dr Cason are also founding members of the Kovsie Brewery (along with Dr Jan-G Vermeulen and Eduan Hellmuth), which is currently being constructed on the UFS Paradys Experimental Farm facility.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept